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Abstract
Telangiectatic adenoma is a new classification of a hepatic lesion. It was previously named
telangiectatic focal nodular hyperplasia but it is in fact true adenoma with telangiectatic features.
We report here a case of telangiectatic adenoma in a 72-year-old woman. The image features are
lack of a central scar, a heterogeneous lesion, hyperintensity in T1-weighted MR images, strong
hyperintensity in T2-weighted MR images, and persistent contrast enhancement in delayed-phase
contrast-enhanced CT or T1-weighted MR images. It is a monoclonal lesion with potential of
malignancy. The treatment of telangiectatic adenoma is surgery, the same way as hepatic adenoma.
Focal nodular hyperplasia may be managed by clinical follow-up alone.
Background
Telangiectatic adenoma (TA), previously known as tel-
angiectatic focal nodular hyperplasia, was recently rede-
fined as a variant of hepatocellular adenoma (HA), based
on molecular and genetic evidence. This redefinition has
potential clinical relevance because telangiectatic adeno-
mas must be as aggressively managed as hepatocellular
adenomas. Here we describe a case of a female patient pre-
senting with a liver mass which turned out to be TA, and
discuss this new pathological entity and its differential
diagnosis, with emphasis on interpretation of imaging
results.
Case presentation
A 72-year-old asymptomatic woman presented to the
clinic for a checkup. She had a history of cholecystectomy,
hypothyroidism, and hypertension. She had been treated
with thyroid hormone (Puran® T4, 75 μg), an anti-hyper-
tensive agent (the angiotensin-converting enzyme inhibi-
tor Enalapril®, 20 mg), an antiarrhythmic drug
(Diltiazem®, 90 mg), and acetylsalicylic acid (200 mg).
She reported use of oral contraceptives for over 30 years.
She had no history of smoking, drinking, drug abuse or
family history of liver disease.
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On physical examination, the liver was palpable to 6.5 cm
from the right costal, and 10 cm from the appendix
xiphoid; it was painless, and had a rugged and hard con-
sistency. Laboratory studies revealed the following: red
blood cells, 3,690,000/mm3; hemoglobin, 11.7 g/dL;
hematocrit, 35%; platelets, 278,000/mm3; cholesterol,
186 mg/dL; triglycerides, 70 mg/dL; glucose, 85 mg/dL;
TSH, 2.8 U/mL; serum creatinine, 0.7 mg/dL; ALT, 47 U/
L; AST, 29 U/L; GGT, 23 U/L; alkaline phosphatase, 138
U/L; TB, 0.8 mg/dL; DB, 0.4 mg/dL; PT, 12 s; INR, 1.0;
PTT, 29 s; folic acid, 11 mg/mL; alpha-fetoprotein, 2.08
ng/mL; iron, 106 μg/dL; vitamin B12, 210 pg/mL; ferritin,
170 mg/L; LDH, 384 IU/L; and CEA 2.4 ng/mL.
Abdominal ultrasound revealed an enlarged and hetero-
geneous liver that contained an expansive and heteroge-
neous lesion measuring 14 × 9.4 cm with poorly defined
limits, including two echogenic nodular areas, measuring
6.3 and 3.2 cm, respectively. The gallbladder was not vis-
ualized.
Computed tomography (CT) of the upper abdomen (Fig-
ure 1) showed a heterogeneous lesion – measuring 15 ×
14 × 10 cm – with a partially well-defined margin and
hypodense permeating areas, some with attenuation val-
ues compatible with soft parts, and others with liquefac-
tion located in the left liver lobe. After endovenous
contrast injection, the lesion showed intense and non-
homogeneous impregnation in the arterial and portal
phases, with hypodense permeated areas located in the
left lobe, notably parts II and III; these areas determined
recoil and reduced the size of vascular structures adjacent
to the liver. The injury also caused bulging of the border
of adjacent liver tissue, causing a compressive effect on
other abdominal structures, especially the stomach and
pancreas.
Magnetic resonance (MR) imaging of the upper abdomen
showed different components within the lesion. T2-
weighted images in the peripheral region showed a dis-
crete heterogeneous hyperintense signal, while the central
portion was hypointense. In T1-weighted images, the sig-
nal in the periphery of the mass was similar to the muscle
signal and the center of the lesion showed a signal that
was clearly hypointense. Although impregnation of both
components began in the arterial phase, the peripheral
region showed a stronger signal during the arterial and
portal phases, followed by signal decay in the late phase
due to relatively rapid washout, indicative of hypervascu-
larization. The center of the mass was far more intense in
the late phase, probably due to slow flow through the vas-
cular components (Figures 2 and 3).
Surgery and pathological analysis revealed a hepatic seg-
ment measuring 17.5 × 14 × 8 cm and weighing 1200 g
that contained a 15 × 9 cm brown tumor with ill-defined
limits. The tumor had a gelatinous component and
showed hemorrhaged, necrotic, and cystic areas. The final
Portal-stage contrast-enhanced helical CT of the upper abdo- men Figure 1
Portal-stage contrast-enhanced helical CT of the 
upper abdomen. Impregnation by the contrast agent 
shows a large, solid, exofitic lesion compromising the left 
liver lobe. The enhancement is intense and heterogeneous, 
the dominant portion being in the periphery of the lesion 
(arrow).
MR imaging sequence with T2-weighted transversal Figure 2
MR imaging sequence with T2-weighted transversal. 
Imaging shows a hypointense signal originating in the periph-
eral region (arrow) and a dominant component associated 
with a hyperintense signal (*).Cases Journal 2009, 2:24 http://www.casesjournal.com/content/2/1/24
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diagnosis was TA. The patient progressed well and she
remains asymptomatic after one year of follow up.
Discussion
Focal nodular hyperplasia (FNH) and liver cell adenoma
(LCA) are the most frequent benign epithelial lesions of
the liver observed in young female patients using oral con-
traceptives. Although they are both benign, the manage-
ment of these two types of lesions is radically different,
consisting of clinical follow-up for FNH and surgical
resection for liver cell adenoma [1,2].
FNH is the second most common benign liver tumor,
occurring predominantly in young and middle-aged
(A) T1-weighted fat-suppressed MR imaging without contrast; and MR imaging after contrast in (B) arterial phase, (C) portal  phase, and (D) late phase Figure 3
(A) T1-weighted fat-suppressed MR imaging without contrast; and MR imaging after contrast in (B) arterial 
phase, (C) portal phase, and (D) late phase. In T1-weighted images without contrast, the signal in the periphery of the 
mass (arrow) is similar to the muscle signal; the center of the lesion clearly shows a hypointense signal (*). Although impregna-
tion of both components began in the arterial phase, the peripheral region (arrow) showed a stronger signal during the arterial 
and portal phases, followed by signal decay in the late phase due to relatively rapid washout, indicative of hypervascularization. 
The enhancement of the central component is far more intense in the late phase (*), probably due to a large interstitial space 
and slow flow through the vascular components.Cases Journal 2009, 2:24 http://www.casesjournal.com/content/2/1/24
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women [3,4]. The tumor-like lesions probably result from
a hyperplastic liver response to a focal blood flow increase
related to pre-existing arterial malformation [4,5]. Their
polyclonal nature suggests that they are part of a regener-
ative process; consequently, they are unlikely to present a
risk of malignancy [1].
FNH is usually asymptomatic and is often discovered for-
tuitously. A non-operative approach has been adopted by
most hepatobiliary centers because there are no proven
cases of malignant degeneration. Pain may sometimes be
present, particularly in the case of a large tumor, but hem-
orrhage is very rarely reported [6]. Unlike adenomas, 70%
of cases of FNH may be diagnosed by imaging techniques
alone [2]. The recommended follow-up consists of serial
ultrasonography. The main goal of imaging in FNH
patients is to firmly establish the diagnosis in order to
avoid surgical resection and to confirm that a conservative
approach to therapy is appropriate [7,8].
LCA is a rare hepatic tumor that is characterized patholog-
ically by the benign proliferation of hepatocytes [4]. These
tumors are strongly associated with oral contraceptive use
[9]. Distinction between LCA and FNH is not possible
based only on clinical and laboratory data.
LCA usually comprises a single nodule; more rarely, mul-
tiple nodules may be present [10,11]. In contrast to regen-
erative lesions such as typical FNHs, LCAs are monoclonal
tumors, suggesting that they display neoplastic rather
than regenerative behavior; consequently, they may
present a risk of malignancy [1]. LCAs are usually sympto-
matic, presenting with abdominal pain or abnormal liver
function tests. Surgical resection is advocated based on the
high incidence of bleeding complications and reports of
neoplastic degeneration [8]. Because of these risks of
spontaneous rupture and malignant transformation,
LCAs must be identified and treated promptly.
Based on previous studies, it is now clear that the lesions
previously named telangiectatic focal nodular hyperpla-
sias are in fact true adenomas with telangiectatic features;
hence they are now referred to as telangiectatic adenomas
(TAs). This new classification is based on both morpho-
logical and molecular features, and takes into considera-
tion the results of clonal analysis and gene expression
studies. It should be emphasized that the new classifica-
tion has clinical relevance; aggressive management of
these cases should be considered. However, it remains to
be established whether the clinical behavior of TAs,
including the associated risk of malignant progression,
resembles that of LCA more than FNH.
TA is defined as a benign well-differentiated proliferation
of hepatocytes in which vascular changes, including tel-
angiectatic features, are prominent [9]. Clonal analysis of
TA showed that most examples displayed an X-chromo-
some inactivation pattern consistent with monoclonality.
This monoclonal nature of TAs suggests that they display
neoplastic rather than regenerative behavior; therefore,
unlike regenerative lesions such as typical FNHs, they may
present a risk of malignancy [1]. Diagnosis of a TA
requires the observation of at least 4 of the following fea-
tures: lack of a central scar, a heterogeneous lesion, hyper-
intensity in T1-weighted MR images, strong
hyperintensity in T2-weighted MR images, and persistent
contrast enhancement in delayed-phase contrast-
enhanced CT or T1-weighted MR images [7].
Benign hepatic tumors represent a broad spectrum of
regenerative and true neoplastic processes. Many of these
tumors present with characteristic features in imaging
studies. The new classification of TAs has clinical rele-
vance because they must be aggressively managed in the
same way as HAs, whereas FNH may be managed by clin-
ical follow-up alone.
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